Researchers discover novel way to develop tumor vaccines

Mar 02, 2008

Researchers at the University of Southern California (USC) have uncovered a new way to develop more effective tumor vaccines by turning off the suppression function of regulatory T cells. The results of the study, titled “A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell-mediated suppression,” will be published in Nature Medicine on March 2, 2008.

“Under normal circumstances, regulatory T cells inhibit the immune system to attack its own cells and tissues to prevent autoimmune diseases. Cancer cells take advantage of regulatory T cells' suppressor ability, recruiting them to keep the immune system at bay or disabling the immune system’s attack provoked by tumor vaccines.” says Si-Yi Chen, M.D., Ph.D., professor of immunology and molecular microbiology at the USC/Norris Comprehensive Cancer Center and the Keck School of Medicine of USC.

“Our study provides a new vaccination strategy to overcome the regulatory T cells’ immune suppression while avoiding non-specific overactivation of autoreactive T cells and pathological autoimmune toxicities.”

The study identified a new molecular player called A20, an enzyme that restricts inflammatory signal transduction in dendritic cells. When it is inhibited, the dendritic cells overproduce an array of cytokines and co-stimulatory molecules that triggers unusually strong immune responses that cannot be suppressed by regulatory T cells. The resulting hyperactivated immune responses triggered by A20-deficient dendritic cells are capable of destroying various types of tumors that are resistant to current tumor vaccines in mice.

“Through a series of immunological studies, we have identified A20 as an essential antigen presentation attenuator that prevents the overactivation and excessive inflammation of the dendritic cells, which, in turn, restricts the potency of tumor vaccines,” says Chen.

The immune system’s dendritic cells are the guardian cells of the immune systems and play an important role in activating immune responses to recognize and destroy tumor cells. Tumor vaccines have been designed and developed to incite the immune response to cancer cells so that the immune system can attack and destroy cancer cells. However, discovering A20’s role in restricting immune responses has led to a method for blocking tumors from using regulatory T cells for protection.

“Despite intensive efforts, tumor vaccines have been largely ineffective in causing tumor regression in the clinic,” says Chen. “The vaccination approach we developed inhibits the key inhibitor in tumor antigen-loaded dendritic cells to selectively hyperactivate immune responses and to tip the balance from immune suppression in tumor-bearing hosts or cancer patients to effective antitumor immunity.”

This approach is capable of overcoming the regulatory T cells’ suppression mechanism and will allow for a new generation of tumor vaccines to be developed. The next step is to translate these findings into a human clinical trial, says Chen.

Source: University of Southern California

Explore further: Growing a blood vessel in a week

add to favorites email to friend print save as pdf

Related Stories

'Stealth' nanoparticles could improve cancer vaccines

Oct 01, 2014

Cancer vaccines have recently emerged as a promising approach for killing tumor cells before they spread. But so far, most clinical candidates haven't worked that well. Now, scientists have developed a new ...

Recommended for you

Growing a blood vessel in a week

1 hour ago

The technology for creating new tissues from stem cells has taken a giant leap forward. Three tablespoons of blood are all that is needed to grow a brand new blood vessel in just seven days. This is shown ...

Testing time for stem cells

4 hours ago

DefiniGEN is one of the first commercial opportunities to arise from Cambridge's expertise in stem cell research. Here, we look at some of the fundamental research that enables it to supply liver and pancreatic ...

Team finds key signaling pathway in cause of preeclampsia

Oct 23, 2014

A team of researchers led by a Wayne State University School of Medicine associate professor of obstetrics and gynecology has published findings that provide novel insight into the cause of preeclampsia, the leading cause ...

Rapid test to diagnose severe sepsis

Oct 23, 2014

A new test, developed by University of British Columbia researchers, could help physicians predict within an hour if a patient will develop severe sepsis so they can begin treatment immediately.

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

superhuman
not rated yet Mar 02, 2008
Great news, I really hope it will work in humans, vaccines would be the most elegant way of dealing with tumors by FAR if only they worked!